Longboard Pharmaceuticals Inc (NAS:LBPH)

$ 59.98 0.02 (0.03%) Market Cap: 2.34 Bil Enterprise Value: 2.06 Bil PE Ratio: 0 PB Ratio: 8.51 GF Score: 35/100

Q2 2024 Longboard Pharmaceuticals Inc Earnings Call and Discussion of Topline Phase 1 SAD Data for LP659 Transcript
Aug 01, 2024

$32.92 (-0.96%)

Earnings
Longboard Pharmaceuticals Inc to Host Call to Discuss Topline Data from the PACIFIC Study Transcript
Jan 02, 2024
Longboard Pharmaceuticals Inc Investor Day Transcript
Oct 11, 2023
Longboard Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 28, 2023
Longboard Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 18, 2023
Q4 2022 Longboard Pharmaceuticals Inc Earnings Call Transcript
Mar 02, 2023

$5.26 (-4.88%)

Earnings
Longboard Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript
Jun 15, 2022
Longboard Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) Transcript
Sep 08, 2021

Longboard Pharmaceuticals Inc to Host Call to Discuss Topline Data from the PACIFIC Study Transcript

Jan 02, 2024 / 01:30PM GMT

Release Date Price: $25.1 (+316.25%)

Transcript 8-K

Operator

Ladies and gentlemen, thank you for standing by. Welcome to Longboard Pharmaceuticals corporate call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question-and-answer session (Operator Instructions)

Please be advised that today's conference is being recorded. I would like now to turn the conference over to Megan Knight, Head of Investor Relations. Please go ahead.

Megan Knight Longboard Pharmaceuticals Inc;Head of Investor Relations

Thank you, operator, and good morning, everyone. Welcome to Longboard's conference call and webcast where we will be discussing top-line data from our Phase 1b/2a clinical trial, the PACIFIC study; evaluating bexicaserin, or LP352 for seizures associated with a broad range of developmental and epileptic encephalopathies or DEEs. Joining me on today's call is Kevin Lind, President and Chief Executive Officer; Dr. Randall Kaye, Chief Medical Officer; and Brandi Roberts, Chief Financial Officer.

Before we begin today. I would like to remind

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.